|
Two compounds do most of the mood-relevant work: crocin, the carotenoid pigment responsible for saffron's color, and safranal, the volatile compound behind its smell. Animal research suggests both inhibit serotonin reuptake in the brain, the same basic mechanism used by prescription SSRIs like fluoxetine.
American kitchens treat saffron as an occasional luxury for color. The Persian tradition was a daily dose dissolved in warm liquid, repeated consistently over weeks.
Multiple double-blind randomized controlled trials, most conducted by Iranian research teams, have tested 30 milligrams per day of saffron extract head-to-head against fluoxetine at 20 milligrams per day for mild to moderate depression. Over six weeks, the two performed comparably on the Hamilton Depression Rating Scale, with no statistically significant difference between them.
A 2021 randomized controlled trial tested saffron specifically in 86 perimenopausal women, administering 28 milligrams per day of standardized extract for twelve weeks. Anxiety scores fell by 33 percent and depression scores by 32 percent from baseline, measured on the Greene Climacteric Scale.
A meta-analysis pooling five randomized trials confirmed that saffron supplementation significantly outperformed placebo for depressive symptoms, with consistent results across different study designs and preparations. Most individual trials enrolled forty to sixty participants and many originated from Iranian research groups, so the evidence base still needs larger and more geographically diverse replication.
That said, the pharmacological mechanism through serotonin reuptake inhibition is not fully understood. The question is not whether saffron acts on serotonin but whether the clinical effect is large and reliable enough to matter outside a controlled trial.
|